Q2 2025 InspireMD Inc Earnings Call Transcript
Key Points
- InspireMD Inc (NSPR) received FDA premarket approval for its CGuard Prime Carotid Stent System, marking a significant milestone for the company.
- The company has commenced its US commercial launch, leveraging experience from over 30 international markets and over 60,000 patients treated.
- InspireMD Inc (NSPR) has built a strong foundation with a world-class team, solid infrastructure, and a sizable balance sheet to support its US launch.
- The company successfully raised $40.1 million through a private placement and $17.9 million from warrant exercises, strengthening its cash position.
- InspireMD Inc (NSPR) is making progress in its clinical pipeline, including pivotal studies in TCAR and acute stroke care, which are critical for long-term growth.
- Total revenue for the second quarter of 2025 increased by only 2% to $1.8 million, with no US commercial revenue recognized in Q2.
- Gross profit decreased by 5.7% to $313,000, with a decline in gross margin from 19.0% to 17.6% due to production variances.
- Operating expenses increased by 55% to $13.3 million, driven by headcount-related expenses and the establishment of a US headquarters.
- Net loss for the second quarter of 2025 totaled $13.2 million, compared to a net loss of $7.9 million in the same period in 2024.
- The timeline for the clearance and launch of the SwitchGuard TCAR device has been extended to 2027, reflecting potential delays in development and regulatory processes.
Good morning, and welcome to InspireMD's second-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Marissa Bych with -- from Gilmartin Group for introductory disclosures.
Thank you for joining us for the InspireMD second quarter 2025 conference call. Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer; and Mike Lawless, Chief Financial Officer.
During this call, management will be making forward-looking statements, not historical facts, which are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements.
For more information about these risks, please refer to the risk factors described in InspireMD's most
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
